WHO updates living guideline on therapeutics and Covid-19, WHO (updated 22nd April 2022)

Update includes strong recommendation for use of nirmatrelvir/ritonavir in those with non-severe illness at highest hospitalisation risk; a conditional recommendation (CR) against use in low risk patients; and CR for use of remdesivir in those at highest risk of hospitalisation.

Source: Current Awareness Service for Health (CASH) - April 25, 2022 Category: Consumer Health News Source Type: news